ValueScreener

Amgen Inc. (AMGN): investment thesis checklist

What a value investor writing down why they own Amgen Inc. would be relying on, read from its filings: the figures that have carried the business, the lines a reader might set on them, and the published tests it meets today. A list to write against, not a view on the company.

1. The figures the case would rest on

  • Return on invested capital: 14.2% in FY2025; between 3.6% and 24.4% over 10 filed years, median 17.4%. Does the thesis need it to stay inside that range?
  • Return on equity: 89.1% in FY2025; between 7.8% and 179.0% over 10 filed years, median 79.1%. Does the thesis need it to stay inside that range?
  • Free cash flow yield: 4.6% in FY2025; between 4.6% and 8.7% over 10 filed years, median 6.9%. Does the thesis need it to stay inside that range?
  • EV to EBIT: 24.64x in FY2025; between 14.46x and 26.52x over 10 filed years, median 18.01x. Does the thesis need it to stay inside that range?
  • Price to earnings: 23.00x in FY2025; between 14.28x and 64.65x over 10 filed years, median 21.79x. Does the thesis need it to stay inside that range?
  • Gross margin: 67.3% in FY2025; between 61.5% and 82.7% over 10 filed years, median 75.7%. Does the thesis need it to stay inside that range?
  • Operating margin: 24.7% in FY2025; between 21.7% and 43.6% over 10 filed years, median 36.1%. Does the thesis need it to stay inside that range?
  • Net debt to EBITDA: 3.25x in FY2025; between 2.05x and 4.55x over 10 filed years, median 2.56x. Does the thesis need it to stay inside that range?
  • Revenue growth, 5-year CAGR: 7.7% in FY2025; between 2.5% and 8.1% over 10 filed years, median 4.2%. Does the thesis need it to stay inside that range?
  • Share count change: 0.2% in FY2025; between -9.5% and 0.6% over 10 filed years, median -2.7%. Does the thesis need it to stay inside that range?

2. What must stay true: guardrails a reader might set

Each line is drafted from Amgen Inc.'s own current figure, never from a level we think a business should clear, and replayed over its filed years. They are a reader's to keep, edit or drop.

  • Debt to Equity stays at or below 8x

    Today 6.4x. Replayed over 10 filed years, it would have broken in 3; most recently FY2024, at 10.36x (10-K, filed 2025-02-14).

  • Return on Invested Capital stays at or above 11.4%

    Today 14.19%. This indicator depends on inputs (market price, multi-statement composites) whose history is not deep enough to re-derive it with the same formula as the live value, so no honest retro-test exists for it.

  • Dividend Rate stays at or above $9.97

    Today $10.08. This indicator depends on inputs (market price, multi-statement composites) whose history is not deep enough to re-derive it with the same formula as the live value, so no honest retro-test exists for it.

Draft your own thesis on AMGN, free

3. What would break it

  • A filed year in which debt to equity rose above 8x.
  • A filed year in which return on invested capital fell below 11.4%.
  • A filed year in which dividend rate fell below $9.97.

4. The published tests it meets today

Of 30 tests value investors published: 2 met, 28 not met, 0 we could not complete. Counts, never a score.

Meets: ROIC at or above WACC; Cash-covered dividend.

What this cannot tell you

What the numbers say today, not the day one stops being true. The reasons are not written down.

An account adds

One email the night a number you wrote down breaks. Silence otherwise.

No card. 30 free days, and nothing is charged unless you choose a plan.

How this is computed

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map
  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.